[go: up one dir, main page]

WO1998035037A1 - Proteines a phosphorylation de tyrosine et associees a un sillon de clivage (pstpip) - Google Patents

Proteines a phosphorylation de tyrosine et associees a un sillon de clivage (pstpip) Download PDF

Info

Publication number
WO1998035037A1
WO1998035037A1 PCT/US1998/001774 US9801774W WO9835037A1 WO 1998035037 A1 WO1998035037 A1 WO 1998035037A1 US 9801774 W US9801774 W US 9801774W WO 9835037 A1 WO9835037 A1 WO 9835037A1
Authority
WO
WIPO (PCT)
Prior art keywords
pstpip
polypeptide
seq
cells
protein
Prior art date
Application number
PCT/US1998/001774
Other languages
English (en)
Other versions
WO1998035037A9 (fr
Inventor
Laurence A. Lasky
Donald J. Dowbenko
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to AU66493/98A priority Critical patent/AU731570B2/en
Priority to US09/068,377 priority patent/US6887705B1/en
Priority to CA002277983A priority patent/CA2277983C/fr
Priority to JP53480098A priority patent/JP3503951B2/ja
Priority to EP98908458A priority patent/EP0980426B1/fr
Priority to IL13095398A priority patent/IL130953A0/xx
Priority to AT98908458T priority patent/ATE278016T1/de
Priority to DE69826649T priority patent/DE69826649T2/de
Publication of WO1998035037A1 publication Critical patent/WO1998035037A1/fr
Publication of WO1998035037A9 publication Critical patent/WO1998035037A9/fr
Priority to IL130953A priority patent/IL130953A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

  • This present invention concerns novel proteins which interact with and are dephosphorylated by PEST- type protein tyrosine phosphatases More particularly, the present invention concerns PSTPIP polypeptides which interact with the protein tyrosine phosphatase enzyme PTP HSCF and which are associated with the polymerization of actm monomers
  • the PEST family of PTPs are a group of phosphatase enzymes
  • PTP PEST [Yang et al , J Biol Chem 268(23) 17650 (1993)]
  • PTP PEP Movablews et al , Mol Cell Biol 12(5) 2396-2405 (1992)]
  • PTP HSCF [Cheng et al , Blood 88(4) 1 156-1 167 (1996), USSN 08/620,526 filed 22 March 1996]
  • PTP-K1 Humanang et al , O cogene 13 1567-1573 (1996)
  • PTP20 [Aoki et al , ./ Biol Chem 271(46) 29422-29426 (1996)] or FLP1 [Dosil et al , ⁇ /oorf 88(12) 4510-4525 ( 1996)]
  • PTP BDP1 Kim et al , Oncogene 13 2275-2279 (1996)
  • PTP PEST is ubiquitously expressed (Yang et al , (1993) supra). PTP PEP is expressed in lymphoid cells (Matthews et al , (1992) supra).
  • PTP HSCF is expressed in hematopoietic stem/progenitor cells and fetal thymus (Cheng et al (1996) supra and Dosil et al , (1996) supra) as well as a subset of adult tissues including bone marrow (Huang et al , (1996) supra) and PTP BDP1 is expressed at low levels in the brain as well as other adult tissues (Kim et al , (1996) supra)
  • PSTPIP proteins which bind to and are dephosphorylated by members of the PEST-type protein tyrosine phosphatases have not been heretofore disclosed Therefore, it is an object of the present invention to provide PSTPIP polypeptides which bind to and are dephosphorylated by members of the PEST-type protein tyrosine phosphatases It is a further object of the present invention to provide nucleic acid encoding the PSTPIP polypeptides so that those polypeptides may be prepared by recombinant DNA techniques
  • Fig 1A (SEQ ID NO 1), (n) a further mammalian homologue of the polypeptide of (l), (in) a polypeptide encoded by nucleic acid which hybridizes under stringent conditions to nucleic acid encoding the polypeptide of (I) or (u) and which substantially retains the ability to bind to a member of the PEST-type protein tyrosine phosphatases. and (iv) a functional derivative of any of the polypeptides ( ⁇ )-( ⁇ n) substantially retaining the ability to bind to a member of the PEST-type protein tyrosine phosphatases.
  • the present invention provides antagonists of the above described PSTPIP polypeptides
  • the present invention provides isolated nucleic acid sequences which encode the above described PSTPIP polypeptides, vectors comprising those nucleic acid sequences operably linked to control sequences recognized by host cells transformed with those vectors and host cells comprising the above described nucleic acid sequences
  • the present invention provides antibodies which are capable of binding to the above described PSTPIP polypeptides and hyb ⁇ doma cell lines which produce such antibodies
  • the antibodies are monoclonal antibodies
  • the present invention also provides a method for producing the above described PSTPIP polypeptides comprising transforming a host cell with nucleic acid encoding the polypeptide cultu ⁇ ng the transformed cell and recovering the polypeptide from the cell culture
  • the present invention provides a method for inducing the polymerization of actm monomers in a eukaryotic cell comprising introducing the above described PSTPIP polypeptide into the cell
  • the present invention also provides an assay for identifying antagonists and agonists of the above described PSTPIP polypeptides comprising contacting the PSTPIP polypeptide with a candidate antagonist or agonist and monitoring the ability of the polypeptide to induce the polymerization of actin monomers
  • the invention concerns an assay for identifying a polypeptide capable of interacting with a PST Phosphatase Interacting Protein (PSTPIP), comprising
  • the present invention further concerns an assay for identifying peptides capable of inhibiting the interaction of a native PST Phosphatase Interacting Protein (PSTPIP) and a native protein tvrosine phosphatase hematopoietic stemcell fraction (PTP HSCF), which comprises contacting said PSPIP and a PTP HSCF, or fragments thereof, with a candidate peptide, and detecting the ability of the PTPPIP and PTP HSCF, of fragments thereof, to interact with each other
  • PSTPIP Phosphatase Interacting Protein
  • PTP HSCF native protein tvrosine phosphatase hematopoietic stemcell fraction
  • FIGS. 2A-2B Northern Blot Analysis of the Expression of PSTPIP Transcript. A.
  • PSTPIP and actin in heart (lane a), brain (lane b), spleen (lane c), lung (lane d) liver (lane e), muscle (lane f), kidney (lane g) and testis (lane h) B.
  • FIG. 3 Interaction Between PTP HSCF and GST-PSTPIP. Shown are precipitations of in vitro transcribed and translated PTP HSCF phosphatase with GST-p85 (lane a), GST alone (lane b), GST-Src (lane c), GST-Grb-2 (lane d), GST-PSTPIP (lane e), GST-AbI (lane f), GST-PLC (lane g), anti-PTP HSCF polyclonal antibody (lane h) and GST-Spect ⁇ n (lane I)
  • FIGS 4A-4D Mapping of the PSTPIP Interaction Site on PTP HSCF.
  • A Shown are PTP HSCF constructs containing full-length, C-terminal homology (CTH) and PST- ⁇ ch domain deletions used for in vitro transcription and translation B.
  • CTH C-terminal homology
  • PST- ⁇ ch domain deletions used for in vitro transcription and translation
  • Lanes are designated as follows full-length PTP HSCF with anti-PTP HSCF (lane a), full-length PTP HSCF with GST-PSTPIP (lane b), PST- ⁇ ch+CTH deleted PTP HSCF with anti-PTP HSCF (lane c), PST- ⁇ ch+CTH deleted PTP HSCF with GST-PSTPIP (lane d), PST- ⁇ ch+CTH deleted PTP HSCF with GST-Spectrin (lane e), CTH-deleted PTP HSCF with GST-Spect ⁇ n (lane f), CTH-deleted PTP HSCF with GST-PSTPIP (lane g), CTH-deleted PTP HSCF with anti-PTP HSCF (lane h) full-length PTP HSCF with anti-PTP HSCF (lane I)
  • FIGS. 5A-5B Mapping of PTP HSCF Interaction Site on PSTPIP.
  • A Shown are GST fusions containing the full-length coiled coil and SH3 domains of PSTPIP
  • B Precipitation of full-length PTP HSCF with GST-full-length PSTPIP (lane a), anti-hemagglutinm (directed against a hemagglutinm epitope tag at the N-termmus of the PTP HSCF) (lane b), GST-Grb2 (lane c) GST-Spect ⁇ n (lane d) GST-full- length PSTPIP (lane e), GST-SH3 PSTPIP (lane f) and GST-coiled coil PSTPIP (lane g)
  • FIGS 6A-6F In vivo Tyrosine Phosphorylation of PSTPIP.
  • A Illustrated is the immunoprecipitation of endogenous PSTPIP from BaO cells with anti-PSTPIP polyclonal antibody in the presence and absence of the PTP inhibitor pervanadate Precipitates were blotted with either anti-PSTPIP ( ⁇ PSTPIP) or anti-phosphotyrosine ( ⁇ PTyr) antibodies Note that the protein in the absence of pervanadate is more diffuse and shows a lower phosphotyros e content than the protein m the presence of the inhibitor B. Shown are lmmunoprecipitations done with the indicated antibodies on cells transfected as illustrated C.
  • FIG. 7 Localization of Endogenous PSTPIP in 3T3 Cells. Shown are confocal images of two different groups of 3T3 cells viewed at different focal planes stained with anti-PSTPIP antibody (Cy3) and phalloidm-FITC (panels a-d) Sites of coloca zation appear yellow and are the cortical actm (c a ), the lamel podia (lam ) and the stress fibers (s f ) Panels e-g illustrate a lower magnification and two high magnification views, respectively, of interphase cells and cells undergoing cytokinesis stained with the same reagents The interphase cells show co-localization predominantly in the cortical actin (c a ) region at this focal plane, while the cells undergoing cytokinesis show colocahzation predominantly at the cleavage furrow (c f ) at both focal planes shown The bars show sizes in microns
  • FIG. 8 Expression of PSTPIP in Transfected 3T3 Cells.
  • Panel a shows a group of 3T3 cells transfected with an expression plasmid containing a C-terminal FLAG version of PSTPIP under the control of the cytomegalovirus promoter Cells were stained with anti-FLAG (Cy3) and phalloidin-FITC PSTPIP co-localizes with actin at the cortical region (c a ), the stress fibers (s f ) and the lamelhpodia (lam )
  • Panels b and c illustrate two cells with abnormal mo ⁇ hology expressing PSTPIP Note that these filopodial structures are greater than 100 microns in length Panel c also illustrates that these cells have a different mo ⁇ hology from normally elongated 3T3 cells
  • CHO cells Chinese Hamster Ovary (CHO) Cells. CHO cells were transfected with plasmids expressing various forms of PST PIP, and the cells were subsequently stained with a rhodamine-conjugated monoclonal antibody directed against a PST PIP C-terminal FLAG epitope Cells were counter-stained with FITC-conjugated phalloidin to illuminate F-actm A. Wild type (full length) PST PIP, B. PST PIP missing the N-termmal 25 am o acids C. PST PIP missing the N-terminal 50 amino acids, D. PST PIP missing the N-terminal 75 amino acids, E. PST PIP with an alanine replacement mutation at tryptophan232
  • FIG. 11 W232A in PST PIP abolishes the PTP HSCF interaction in vitro. Wild type and mutant forms of PST PIP were transcribed and translated in vitro The upper panel illustrates immunoprecipitation of the proteins with an antibody directed against a PST PIP C-terminal FLAG epitope The lower panel illustrates the same proteins precipitated with a GST fusion protein containing the C-terminal 149 amino acids of PTP HSCF including the C-termmal proline rich binding site The W232A mutation in abolishes the interaction between PST PIP and PTP HSCF, while the other mutations, which were selected because of their similarity to those found in WW-tvpe domains (Chen et al J Biol Chem 272(27) 17070- 17077 ( 1997)) have little effect on binding
  • FIG. 14 In vitro and in vivo analysis of mutations of the C-terminus of PTP HSCF.
  • the third panel illustrates immunoprecipitations of the in vitro transcribed and translated PTP HSCF mutants with a monoclonal antibody directed against an N-terminal HA tag to insure that all the mutants were produced
  • Multiple bands precipitated with the GST PST PIP fusion protein are apparently C-terminal proteolyzed products of the PTP
  • COS cells were co-transfected with a 10 1 ratio of plasmids encoding hemagglutinin (HA) tagged PTP HSCF with the illustrated alanine substitutions or a mutant of PTP HSCF deleted for the C-terminal 24 amino acids (PTP HSCFD24) and wild type PST PIP with a C-tetmmal FLAG epitope tag, respectively
  • Transfected cell lysates were immunoprecipitated with anti-HA monoclonal antibodies and the precipitates were blotted with anti-PST PIP polyclonal antibody to detect the relative amounts of PST PIP complexed with either wild type or different mutant forms of PTP HSCF Lysates were also immunoprecipitaed with anti-HA antibody and blotted with the same antibody to insure equal expression of PTP HSCF Equal expression of PSTPIP was determined by lmmunoprecipitating lysates with anti-FLAG monoclonal antibody and blotting with anti-PST
  • PSTPIP polypeptide
  • PST Phosphatase Interacting Protein
  • HSCF interacting protein are used interchangeably and refer to a polypeptide which comprises the amino acid sequence of the PSTPIP polypeptide shown in Fig 1 A (SEQ ID NO 1) or a further mammalian homologue thereof
  • the above terms are also intended to encompass functional polypeptides encoded by nucleic acid which hybridizes under stringent conditions to nucleic acid which encodes a polypeptide comprising the amino acid sequence of the PSTPIP polypeptide shown in Fig 1A (SEQ ID NO 2) or a further mammalian homologue thereof as well as functional derivatives of any of the above polypeptides
  • PSTPIP polypeptide from a mammalian species other than murine which is functionally similar to the PSTPIP polypeptide shown in Fig 1 A (SEQ ID NO 1)
  • PSTPIP homologues may be identified in such mammals as, for example, human, rabbit, rat, porcine, non-human primates, equine and ovine Screening cDNA libraries prepared from these mammals with a probe derived from the nucleic acid encoding the murine PSTPIP polypeptide shown m Fig 1 A (SEQ ID NO 2) will allow identification of such homologues, such as the human homologue (SEQ ID NOS 28 and 29)
  • native PSTPIP polypeptide in this context refers to a naturally occurring PSTPIP polypeptide, having the described properties, of any human or non-human animal species, with or without the initiating methionine, whether purified from the native source, synthesized, produced by recombinant DNA technology or by any combination of these and/or other methods
  • Native PSTPIP polypeptide specifically includes the native murine PSTPIP protein shown in Fig 1 A (SEQ ID NO 1), and the native human PST PIP protein (SEQ ID NO 29)
  • a "functional derivative" of a polypeptide is a compound having a qualitative biological activity in common with the native polypeptide
  • a functional derivative of a native PSTPIP polypeptide is a compound that has a qualitative biological activity in common with a native PSTPIP polypeptide, for example, as being capable of binding to a member of the PEST-type protein tyrosine phosphatase family and/or being dephosphorylated by a member of the PEST-type protein tyros
  • biological activity in the context of the definition of functional derivatives is defined as the possession of at least one physiological function qualitatively in common with a native polypeptide
  • the functional derivatives of the native PSTPIP of the present invention are unified by their qualitative ability to bind to a member of the PEST-type protein tyrosine phosphatases
  • PEST-type protein tyrosine phosphatase is meant a protein tyrosine phosphatase enzyme which possesses a non-catalytic domain comprising a variable sized region that is rich in proline, serine and threonine residues and a C-terminal 20 amino acid segment which is rich in proline residues and which defines at least one potential SH3 binding domain [Pawson, Nature 373 573-580 (1995)] Included within the PEST- type protein tyrosine phosphatase family are the protein tvrosme phosphatases PTP PEST [Yang et al , (1993) supra], PTP PEP [Matthews et al , (1992) supra].
  • PTP HSCF Choeng et al , (1996) supra]
  • PTP- Kl Huang et al , (1996) supra]
  • PTP20 Aoki et al , (1996) supra] or FLP1 [Dosil et al , (1996) supra]
  • PTP BDP1 Kim et al , (1996) supra]
  • agonist is used to refer to peptide and non-peptide analogs of the native PSTPIP polypeptides of the present invention and to antibodies specifically binding native PSTPIP provided that they retain at least one biological activity of a native PSTPIP
  • the agonists of the present invention retain the qualitative ability to bind to a member of the PEST-type protein tyrosine phosphatases and/or induce the polymerization of actin monomers
  • antagonists are used to refer to a molecule inhibiting a biological activity of a native PSTPIP polypeptide of the present invention
  • the antagonists herein inhibit the ability of the PSTPIP polypeptide of the present invention to bind to members of the PEST-type protein tyrosine phosphatase enzymes It is also preferred that antagonists inhibit the ability of the PSTPIP polypeptide to induce the polymerization of actin monomers
  • Agonist and antagonist candidates may comprise a variety of different compounds including peptides, proteins, organic molecules, and the like For example, it is well within the skill level in the art to prepare combinatorial o gopeptide libraries and screen those libraries for members which either bind to the PSTPIP polypeptide or which interfere with the binding of a PSTPIP polypeptide to a member of the PEST- type protein tyrosine phosphatases
  • Identity or “homology” with respect to a native polypeptide and its functional derivative is defined herein as the percentage of ammo acid residues in the candidate sequence that are identical with the residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity Neither N- or C-terminal extensions nor insertions shall be construed as reducing identity or homology Methods and computer programs for the alignment are well known in the art
  • am o acid and amino acids refer to all naturally occurring L- ⁇ -amino acids
  • D-amino acids may be present in the polypeptides or peptides of the present invention in order to facilitate conformational restriction
  • a D amino acid cysteme may be provided at one or both termini of a peptide functional derivative or peptide antagonist of the native PSTPIP polypeptide of the present invention
  • the amino acids are identified by either the single-letter or three-letter designations
  • ammo acids may be classified according to the chemical composition and properties of their side chains They are broadly classified into two groups, charged and uncharged Each of these groups is divided into subgroups to classify the amino acids more accurately
  • amino acid sequence variant refers to molecules with some differences in their amino acid sequences as compared to a native ammo acid sequence
  • substitutional variants are those that have at least one amino acid residue in a native sequence removed and a different ammo acid inserted in its place at the same position
  • the substitutions may be single, where only one amino acid in the molecule has been substituted, or they may be multiple, where two or more amino acids have been substituted in the same molecule
  • Insertional variants are those with one or more amino acids inserted immediately adjacent to an amino acid at a particular position in a native sequence Immediately adjacent to an amino acid means connected to either the ⁇ -carboxy or ⁇ -amino functional group of the amino acid
  • Deletional variants are those with one or more amino acids in the native ammo acid sequence removed Ordinarily, deletional variants will have one or two amino acids deleted in a particular region of the molecule
  • Antibodies (Abs) and “immunoglobulins (Igs)” are glycoproteins having the same structural characteristics While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas
  • Native antibodies and immunoglobulins are usually heterotetrame ⁇ c glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes Each heavy and light chain also has regularly spaced intrachain disulfide bridges Each heavy chain has at one end a variable domain (Vr j ) followed by a number of constant domains Each light chain has a variable domain at one and (V j J and a constant domain at its other end.
  • Vr j variable domain followed by a number of constant domains
  • the constant domain of the light chain is aligned with the first constant domain of the heavy chain
  • the light chain variable domain is aligned with the variable domain of the heavy chain
  • Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains (Clothia et al , J Mol Biol 186 651-663 (1985) and Novotny and Haber, Proc Natl Acad Sci USA 82 4592- 4596 (1985))
  • variable refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen
  • CDRs complementarity determining regions
  • hyperva ⁇ able regions both in the light chain and the heavy chain variable domains
  • the more highly conserved portions of variable domains are called the framework (FR)
  • the variable domams of native heavy and light chams each comprise four FR regions, largely adopting a ⁇ -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the ⁇ -sheet structure
  • the CDRs m each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies (see Rabat et al , Sequences of Proteins of Immunological Interest, National Institute of Health, Bethesda, MD (1991))
  • the CDRs m each chain are held together in close proximity by the FR
  • Papain digestion of antibodies produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily Pepsin treatment yields an F(ab') fragment that has two antigen combining sites and is still capable of cross-linking antigen
  • Fv is the minimum antibody fragment which contains a complete antigen recognition and binding site This region consists of a dimer of one heavy and one light chain variable domain in tight, non-covalent association It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the V H -V L dimer Collectively, the six CDRs confer antigen binding specificity to the antibody However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site
  • the Fab fragment also contains the constant domain of the light chain and the first constant domain (CHI) of the heavy chain Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region Fab'-SH is the designation herein for Fab' in which the cysteme res ⁇ due(s) of the constant domains bear a free thiol group F(ab') 2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them Other, chemical couplings of antibody fragments are also known
  • the light chains of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (K) and lambda ( ⁇ ), based on the amino acid sequences of their constant domains
  • immunoglobulins can be assigned to different classes There are five major classes of immunoglobulins IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses (isotypes), e g IgG-1, IgG- 2, IgG-3, and IgG-4, IgA-1 and IgA-2
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , delta, epsilon, ⁇ , and ⁇ , respectively
  • the subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known
  • antibody is used in the broadest sense and specifically covers single monoclonal antibodies (including agonist and antagonist antibodies), antibody compositions with polyepitopic specificity, as well as antibody fragments (e g , Fab, F(ab') 2 , and Fv), so long as they exhibit the desired biological activity
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, l e , the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts Monoclonal antibodies are highly specific, being directed against a single antigenic site Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hyb ⁇ doma culture, uncontaminated by other immunoglobulins The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hyb ⁇ dom
  • the monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the cha ⁇ n(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U S Patent No 4,816,567 by Cabilly et al , Morrison et al , Proc Natl Acad Sci USA 81 6851-6855 (1984))
  • humanized forms of non-human (e g murine) antibodies are chimeric immunoglobulins. immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non- human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity
  • CDR complementary determining region
  • donor antibody such as mouse, rat or rabbit having the desired specificity, affinity and capacity
  • Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues
  • humanized antibody may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences
  • progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations Mutant progeny that have the same function or biological property, as screened for in the originally transformed cell, are included
  • the terms "rep cable expression vector” and "expression vector” refer to a piece of DNA, usually double-stranded, which may have inserted into it a piece of foreign DNA Foreign DNA is defined as heterologous DNA, which is DNA not naturally found in the host cell
  • the vector is used to transport the foreign or heterologous DNA into a suitable host cell Once in the host cell, the vector can replicate independently of the host chromosomal DNA, and several copies of the vector and its inserted (foreign) DNA may be generated In addition, the vector contains the necessary elements that permit translating the foreign DNA into a polypeptide Many molecules of the polypeptide encoded by the foreign DNA can thus be rapidly synthesized
  • control sequences refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism
  • the control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence a ⁇ bosome binding site, and possibly, other as yet poorly understood sequences
  • Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers
  • Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence
  • DNA for a presequence or a secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence
  • a ⁇ bosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation
  • "operably linked” means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase
  • enhancers do not have to be contiguous Linking is accomplished by ligation at convenient restriction sites If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice
  • Immunoadhesins or "PSTPIP - immunoglobulin chimeras” are chimeric antibody-like molecules that combine the functional doma ⁇ n(s) of a binding protein (usually a receptor, a cell-adhesion molecule or a ligand) with the an immunoglobulin sequence
  • a binding protein usually a receptor, a cell-adhesion molecule or a ligand
  • the most common example of this type of fusion protein combines the hinge and Fc regions of an immunoglobulin (Ig) with domains of a protein that recognizes and binds to a specific ligand
  • This type of molecule is called an "immunoadhesin", because it combines “immune” and "adhesion" functions, other frequently used names are "Ig-chimera", “Ig-” or “Fc-fusion protein", or “receptor-globulin " "Ohgonucleotides” are short length, single- or double-stranded
  • Transformation means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integration
  • transformation is done using standard techniques appropriate to such cells
  • the calcium treatment employing calcium chloride as described by Cohen, Proc Natl Acad Sci USA 69 21 10 (1972) and Mandel et al , J Mol Biol 53 154 (1970), is generally used for prokaryotes or other cells that contain substantial cell-wall barriers
  • the calcium phosphate precipitation method of Graham and van der Eb, Virology 52 456-457 (1978) is preferred General aspects of mammalian cell host system transformations have been described by Axel in U S Pat No 4,399,216 issued August 16, 1983 Transformations into yeast are typically carried out according to the method of Van Sohngen et al J Bad 130 946 (1977) and Hsiao et al , Proc Natl Acad Sci USA 76 3829 (1979)
  • other methods for transformation employing calcium chloride, as described by Cohen, Proc Natl
  • Ligase' T4 DNA hgase
  • Nucleic acids encoding the native PSTPIP proteins of the present invention may be isolated from cDNA or genomic libraries
  • a suitable cDNA library can be constructed by obtaining polyadenylated mRNA from cells known to express the desired PSTPIP protein (for example BaO, available through the American Type Culture Collection), and using the mRNA as a template to synthesize double stranded cD
  • a mRNA encoding the native PSTPIP of the present invention is expressed for example, in tissues derived from adult lung and spleen as well as in very early 7 day murine embryos
  • the gene encoding the novel PSTPIP polypeptide of the present invention can also be obtained from a genomic library, such as a human genomic cosmid library, or a mouse-derived embryonic cell (ES) genomic library
  • probes either cDNA or genomic, are then screened with probes designed to identify the gene of interest or the protein encoded by it
  • suitable probes include monoclonal and polyclonal antibodies that recognize and specifically bind to a PSTPIP polypeptide
  • suitable probes include carefully selected oligonucleotide probes (usually of about 20-80 bases in length) that encode known or suspected portions of a PSTPIP polypeptide from the same or different species, and/or complementary or homologous cDNAs or fragments thereof that encode the same or a similar gene
  • Appropriate probes for screening genomic DNA libraries include, without limitation, ohgonucleotides, cDNAs or fragments thereof that encode the same or a similar gene, and/or homologous genomic DNAs or fragments thereof Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures as described in Chapters 10-12 of Sambrook et al , Molecular Cloning A Laboratory Manual, New York, Cold Spring Harbor Laboratory Press
  • DNA encoding a polypeptide of the present invention is isolated by using carefully selected oligonucleotide sequences to screen cDNA libraries from various tissues, the oligonucleotide sequences selected as probes should be sufficient in length and sufficiently unambiguous that false positives are minimized
  • the actual nucleotide sequence(s) is/are usually designed based on regions which have the least codon redundance
  • the ohgonucleotides may be degenerate at one or more positions The use of degenerate ohgonucleotides is of particular importance where a library is screened from a species in which preferential codon usage is not known
  • the oligonucleotide must be labeled such that it can be detected upon hybridization to DNA in the library being screened
  • the preferred method of labeling is to use ATP (e g , ⁇ 32 P) and polynucleotide kinase to radiolabel the 5' end of the oligonucleotide
  • ATP e g , ⁇ 32 P
  • polynucleotide kinase to radiolabel the 5' end of the oligonucleotide
  • other methods may be used to label the oligonucleotide, including, but not limited to, biotinylation or enzyme labeling cDNAs encoding PSTPIP polypeptides can also be identified and isolated by other known techniques of recombinant DNA technology, such as by direct expression cloning, or by using the polymerase chain reaction (PCR) as described in U S Patent No 4,683, 195, issued 28 July 1987, in section 14 of Sambrook et al , supra,
  • cDNAs from other species can also be obtained by cross-species hybridization
  • human or other mammalian cDNA or genomic libraries are probed by labeled oligonucleotide sequences selected from known PSTPIP sequences (such as murine PSTPIP) in accord with known criteria, among which is that the sequence should be sufficient in length and sufficiently unambiguous that false positives are minimized
  • PSTPIP sequences such as murine PSTPIP
  • a 32 P-labeled oligonucleotide having about 30 to 50 bases is sufficient, particularly if the oligonucleotide contains one or more codons for methionine or tryptophan Isolated nucleic acid will be DNA that is identified and separated from contaminant nucleic acid encoding other polypeptides from the source of nucleic acid Hybridization is preferably performed under "stringent conditions", as herein above defined
  • the gene encoding a particular PSTPIP polypeptide can also be obtained by chemical synthesis, following one of the methods described in Engels and Uhlmann, Agnew Chem Int Ed Engl 28 716 (1989) These methods include t ⁇ ester, phosphite, phosphoramidite and H- phosphonate methods, PCR and other autop ⁇ mer methods, and oligonucleotide syntheses on solid supports 2.
  • nucleic acid encoding PSTPIP is available, it is generally ligated into a rephcable expression vector for further cloning (amplification of the DNA), or for expression
  • Expression and cloning vectors are well known in the art and contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells
  • the selection of the appropriate vector will depend on 1) whether it is to be used for DNA amplification or for DNA expression, 2) the size of the DNA to be inserted into the vector, and 3) the host cell to be transformed with the vector
  • Each vector contains various components depending on its function (amplification of DNA of expression of DNA) and the host cell for which it is compatible
  • the vector components generally include, but are not limited to, one or more of the following a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence Construction of suitable vectors containing one or more of the above listed components, the desired coding and control sequences, employs standard ligation techniques Isolated plasmids or DNA fragments are cleaved, tailored, and rehgated in the form desired to generate the plasmids required For analysis to confirm correct sequences in
  • Suitable host cells may also derive from multicellular organisms Such host cells are capable of complex processing and glycosylation activities
  • any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture, although cells from mammals such as humans are preferred
  • invertebrate cells include plants and insect cells Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Snodoptera frugiperda (cate ⁇ illar), Aedes aegvpti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mo ⁇ host cells have been identified See, e g Luckow et al , Bio/Technology 6 47-55 (1988), Miller et al , in Genetic Engineering, Setlow, J K et al , eds , Vol 8 (Plenum Publishing, 1986), pp 277-279, and Maeda et al , Nature 3
  • Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts Typically, plant cells are transfected by incubation with certain strains of the bacterium Agrobacterium tumefaciens. which has been previously manipulated to contain the PSTPIP DNA During incubation of the plant cell culture with A tumefaciens.
  • DNA encoding a PSTPIP polypeptide is transferred to the plant cell host such that it is transfected, and will, under appropriate conditions, express the PSTPIP DNA
  • regulatory and signal sequences compatible with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences Depicker et al , J Mol Appl Gen 1 561 (1982)
  • DNA segments isolated from the upstream region of the T-DNA 780 gene are capable of activating or increasing transcription levels of plant-expressible genes in recombinant DNA-contaimng plant tissue See EP 321 196 published 21 June 1989
  • mice sertolh cells monkey kidney cells (CV1 ATCC CCL 70), African green monkey kidney cells (VERO-76, ATCC CRL-1587), human cervical carcinoma cells (HELA, ATCC CCL 2), canine kidney cells (MDCK, ATCC CCL 34), buffalo rat liver cells (BRL 3A, ATCC CRL 1442), human lung cells (W138, ATCC CCL75), human liver cells (Hep G2, HB 8065), mouse mammary tumor (MMT 060562, ATCC CCL51), TR1 cells [Mather et al , Annals N Y Acad Sci 383 44068 (1982)], MRC 5 cells, FS4 cells, and a human hepatoma cell line (Hep G2) Preferred host cells are human embryonic kidney 293 and Chinese hamster ovary cells
  • transient expression involves the use of an expression vector that is able to replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector
  • Transient systems comprising a suitable expression vector and a host cell, allow for the convenient positive identification of polypeptides encoded by clones DNAs, as well as for the rapid screening of such polypeptides for desired biological or physiological properties
  • transient expression systems are particularly useful in the invention for pu ⁇ oses of identifying analogs and variants of a PSTPIP polypeptide
  • Prokaryote cells used to produced the PSTPIP polypeptides of this invention are cultured in suitable media as describe generally in Sambrook et al , supra
  • Mammalian cells can be cultured in a variety of media
  • Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium (MEM, Sigma), RPMI-1640 (Sigma), and Dulbecco s Modified Eagle's Medium (DMEM, Sigma) are suitable for cultu ⁇ ng the host cells
  • any of the media described in Ham and Wallace, Meth Enzvmol 58 44 (1979), Barnes and Sato, Anal Biochem 102 255 ( 1980), US 4 767,704, 4,657,866, 4,927,762, or 4 560,655 WO 90/03430, WO 87/00195 or US Pat Re 30,985 may be used as culture media for the host cells Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transfer ⁇ n, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as aden
  • the host cells referred to in this disclosure encompass cells in in vitro cell culture as well as cells that are within a host animal or plant
  • PSTPIP polypeptides of this invention may be produced by homologous recombination, or with recombinant production methods utilizing control elements introduced into cells already containing DNA encoding the particular PSTPIP polypeptide
  • Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc Natl Acad Sci USA 11 5201-5205 (1980)], dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein Various labels may be employed most commonly radioisotopes, particularly 32 P However, other techniques may also be employed, such as using biotin-modified nucleotides for introduction into a polynucleotide The biotin then serves as a site for binding to avidm or antibodies, which may be labeled with a wide variety of labels, such as radionuclides, fluorescers, enzymes, or the like Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes The antibodies in turn may be labele
  • Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any animal Conveniently, the antibodies may be prepared against a native PSTPIP polypeptide, or against a synthetic peptide based on the DNA sequence provided herein as described further herembelow
  • Ammo acid sequence variants of native PSTPIP polypeptides are prepared by methods known in the art by introducing appropriate nucleotide changes into a PSTPIP DNA, or by in vitt o synthesis of the desired polypeptide
  • There are two principal variables in the construction of amino acid sequence variants the location of the mutation site and the nature of the mutation With the exception of naturally-occurring alleles, which do not require the manipulation of the DNA sequence encoding the PSTPIP.
  • the amino acid sequence variants of PSTPIP polypeptides are preferably constructed by mutating the DNA, either to arrive at an allele or an amino acid sequence variant that does not occur in nature
  • Non-conservative substitutions within this region may result in PSTPIP variants which lose their ability to be bound and/or dephosphorylated by PTP HSCF (or any other PEST PTP) PSTPIP variants mutated to alter their ability to associate with actin will be useful, for example, as mducers or inhibitors of cytokinesis
  • the coiled-coil domain is defined as extending from about amino acid position 30 to about amino acid position 261 (see Figure 1 A)
  • the coiled-coil domain may be viewed as starting at the N-terminus of the PSTPIP protein Mutational analysis revealed that the six cysteme residues present within this region are not critical for the correct folding and function of PSTPIP
  • the tryptophan (W) residue at amino acid position 232 of the murine sequence was found to be critical for binding PTP HSCF Mutation of this tryptophan residue to alanine resulted in a complete loss of binding
  • the tryptophan at position 232 must be retained, although substitution by other aromatic amino acids, e g tyrosine and phenylalanme might result in variants which retain their ability to bind PTP HSCF to some extent Conversely, if variants that do not bind PTP
  • tryptophan residue at position 232 of SEQ ID NO 1 plays a critical role m PTP HSCF binding
  • tryptophan at position 205, the phenylalanme at position 221 and leucine at position 224 are not critical, and can be readily mutated
  • amino acid alterations can be made at sites that differ in PSTPIP proteins from various species, or in highly conserved regions, depending on the goal to be achieved Sites at such locations will typically be modified in series, e g by (1) substituting first with conservative choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue or residues, or (3) inserting residues of the same or different class adjacent to the located site, or combinations of options 1 -3
  • One helpful technique is called “alanine scanning” (Cunningham and Wells, Science 244. 1081-1085 [1989])
  • Naturally-occurring amino acids are divided into groups based on common side chain properties ( 1) hydrophobic norleucme, met, ala, val, leu, lie (2) neutral hydrophobic cys, ser, thr.
  • substitutions involve exchanging a member within one group for another member within the same group, whereas non-conservative substitutions will entail exchanging a member of one of these classes for another
  • Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative, I e differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain
  • substitutions which in geneial are expected to produce the greatest changes in the properties of the novel native PSTPIP polypeptides of the present invention will be those in which (a) a hydrophilic residue, e g seryl or threonyl, is substituted for (or by) a hydrophobic residue, e g leucyl, isoleucyl, phenylalanyl,
  • Ammo acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically are contiguous
  • the results discosed in the examples show that the N-terminus of PSTPIP is required for the formation of a correctly folded protein that is capable of binding PTPHSCF Accordingly, if structural integrity and biological activity are to be retained, any N-terminal deletion should not extend beyond about amino acid 25 of the murine PSTPIP sequence or the corresponding amino acid in the human or other mammalian sequences
  • the presence of the C-terminal portion of the PSTPIP proteins is less critical
  • the coiled-coil domain is sufficient for proper folding of the protein, as attested by data showing that transfection of the coiled-coil domain of PSTPIP results in co-localization of the protein with the cortical actin cytoskeleton and the lamelhpodia, an event which presumably requires a correctly folded protein
  • Figure 1A in the murine PSTPIP sequence (SEQ ID NO 1) the coiled-coil
  • Ammo acid insertions include ammo- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple ammo acid residues
  • Intrasequence insertions may range generally from about 1 to 10 residues, more preferably 1 to 5 residues, more preferably 1 to 3 residues
  • terminal insertions include the PSTPIP polypeptides with an N-termmal methionyl residue, an artifact of its direct expression in bacterial recombinant cell culture, and fusion of a heterologous N-termmal signal sequence to the N-terminus of the PSTPIP molecule to facilitate the secretion of the mature PSTPIP from recombinant host cells
  • Such signal sequences will generally be obtained from. and thus homologous to, the intended host cell species Suitable sequences include STII or Ipp for E coli.
  • insertional variants of the native PSTPIP molecules include the fusion of the N- or C- terminus of the PSTPIP molecule to lmmunogemc polypeptides, e g bacterial polypeptides such as beta- lactamase or an enzyme encoded by the E coli trp locus, or yeast protein, and C-terminal fusions with proteins having a long half-life such as immunoglobulin regions (preferably immunoglobulin constant regions), albumin, or fer ⁇ tin, as described in WO 89/02922 published on 6 April 1989
  • immunologically active derivatives of the novel PSTPIP polypeptides which comprise the PSTPIP polypeptide and a polypeptide containing an epitope of an immunologically competent extraneous polypeptide, l e a polypeptide which is capable of eliciting an immune response in the animal to which the fusion is to be administered or which is capable of being bound by an antibody raised against an extraneous polypeptide
  • immunologicallv competent polypeptides are allergens, autoimmune epitopes, or other potent immunogens or antigens recognized by preexisting antibodies in the fusion recipient, including bacterial polypeptides such as frpLE, ⁇ -galactosidase, viral polypeptides such as he ⁇ es gD protein, and the like lmmunogemc fusions are produced by cross-linking in vitro or by recombinant cell culture transformed with DNA encoding an lmmunogemc polypeptide It is pre
  • the gene encoding a PSTPIP variant can, for example, be obtained by chemical synthesis using well known techniques More preferably, DNA encoding a PSTPIP ammo acid sequence variant is prepared by site-directed mutagenesis of DNA that encodes an earlier prepared variant or a nonva ⁇ ant version of the PSTPIP Site-directed (site-specific) mutagenesis allows the production of PSTPIP variants through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed Typically, a primer of about 20 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered In general, the techniques of site-specific mutagenesis are well known in the art, as exemplified by publications such as Edelman et
  • reaction vial is removed from the thermal cycler and the aqueous phase transferred to a new vial, extracted with phenol/chloroform (50 50 vol), and ethanol precipitated, and the DNA is recovered by standard procedures This material is subsequently subjected to appropriate treatments for insertion into a vector
  • phagemid display method may be useful in making amino acid sequence variants of native or variant PSTPIP polypeptides or their fragments
  • This method involves (a) constructing a replicable expression vector comprising a first gene encoding a receptor to be mutated, a second gene encoding at least a portion of a natural or wild-type phage coat protein wherein the first and second genes are heterologous, and a transcription regulatory element operably linked to the first and second genes, thereby forming a gene fusion encoding a fusion protein, (b) mutating the vector at one or more selected positions within the first gene thereby forming a family of related plasmids, (c) transforming suitable host cells with the plasmids, (d) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein, (e) cultu ⁇ ng the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing
  • helper phage selected from M13K07, M 13R408, M13-VCS, and Phi X 174
  • the preferred helper phage is M13K07
  • the preferred coat protein is the M13 Phage gene III coat protein
  • the preferred host is E coli, and protease-deficient strains of £ coli
  • Glycosylation variants are included within the scope of the present invention They include variants completely lacking in glycosylation (unglycosylated) variants having at least one less glycosylated site than the native form (deglycosylated) as well as variants in which the glycosylation has been changed Included are deglycosylated and unglycosylated amino acid sequences variants, deglycosylated and unglycosylated native PSTPIP, and other glycosylation variants
  • substitutional or deletional mutagenesis may be employed to eliminate the N- or O-linked glycosylation sites in the a native or variant PSTPIP molecule of the present invention, e g the asparagine residue may be deleted or substituted for another basic residue such as lysine or histidine Alternatively, flanking residues making up the glycosylation site may be substituted or deleted, even though the asparagine residues remain unchanged, in order to prevent glycosylation by eliminating the glycosylation recognition site
  • unglycosylated PSTPIP polypeptides which have the glycosylation sites of a native molecule may be produced in recombinant prokaryotic cell culture because prokaryotes are incapable of introducing glycosylation into polypeptides
  • Glycosylation variants may be produced by selecting appropriate host cells or by in vitro methods
  • Yeast and insect cells introduce glycosylation which varies significantly from that of mammalian systems
  • mammalian cells having a different species e g hamster, murine, porcine, bovine or ovine
  • tissue origin e g lung, liver, lymphoid, mesenchymal or epidermal
  • In vitro processing of the PSTPIP typically is accomplished by enzymatic hydrolysis, e g neuraminidase digestion
  • PSTPIP polypeptides Covalent modifications of PSTPIP polypeptides are included within the scope herein Such modifications are traditionally introduced by reacting targeted amino acid residues of the PSTPIP polypeptides with an organic de ⁇ vatizing agent that is capable of reacting with selected sites or terminal residues, or by harnessing mechanisms of post-translational modifications that function in selected recombinant host cells
  • the resultant covalent derivatives are useful in programs directed at identifying residues important for biological activity, for immunoassays of the PSTPIP, or for the preparation of anti-PSTPIP antibodies for lmmunoaffinity purification of the recombinant
  • complete mactivation of the biological activity of the protein after reaction with mnhyd ⁇ n would suggest that at least one arg yl or lysyl residue is critical for its activity, whereafter the individual residues which were modified under the conditions selected are identified by isolation of a peptide fragment containing the modified amino acid residue
  • Cysteinyl residues most commonly are reacted with ⁇ -haloacetates (and corresponding amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives
  • Cysteinyl residues also are de ⁇ vatized by reaction with bromot ⁇ fluoroacetone, ⁇ -bromo- ⁇ -(5
  • lmidoesters such as methyl picohnimidate, py ⁇ doxal phosphate, py ⁇ doxal, chloroborohyd ⁇ de, t ⁇ nitrobenzenesulfonic acid, O-methylisourea, 2,4- pentanedione, and transaminase-catalyzed reaction with glyoxylate
  • Argmyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butaned ⁇ one, 1,2-cyclohexaned ⁇ one, and ninhyd ⁇ n De ⁇ vatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pK a of the guanidine functional group Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group
  • tyrosyl residues may be made, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetramtromethane
  • aromatic diazonium compounds or tetramtromethane Most commonly, N-acetyhmidizole and tetramtromethane are used to form O-acetyl tyrosyl species and 3- nitro derivatives, respectively
  • Tyrosyl residues are lodinated using 125 I or 13 1 I to prepare labeled proteins for use in radioimmunoassay
  • Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodnmides
  • aspartyl and glutamvl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions
  • Glutaminyl and asparaginyl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues Alternatively, these residues are deamidated under mildly acidic conditions Either form of these residues falls within the scope of this invention
  • Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the ⁇ -amino groups of lysine, arginine, and histidine side chains (T E Creighton, Proteins Structure and Molecular Properties, W H Freeman & Co ,
  • the molecules may further be covalently linked to nonproteinaceous polymers, e g polyethylene glycol, polypropylene glycol or polyoxyalkylenes, in the manner set forth in U S patents
  • cross-linking agents include l,l-b ⁇ s(d ⁇ azoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccimmide esters, homobifunctional lmidoesters, and bifunctional maleimides
  • De ⁇ vatizmg agents such as methyl-3-[(p- az ⁇ dophenyl)d ⁇ th ⁇ o]prop ⁇ o ⁇ m ⁇ date yield photoactivatable intermediates which are capable of forming cross- links in the presence of light
  • reactive water insoluble matrices such as cyanogen bromide activated carbohydrates and the systems reactive substrates described in U S Patent Nos 3,959,642, 3,969,287, 3,691,016, 4,195
  • nonproteinaceous polymer ordinarily is a hydrophihc synthetic polymer, I e a polymer not otherwise found in nature
  • polymers which exist in nature and are produced by recombinant or in vitro methods are useful, as are polymers which are isolated from nature
  • Hydrophihc poly vinyl polymers fall within the scope of this invention, e g polyvmylalcohol and polyvinylpyrro done Particularly useful are polyvinylalkylene ethers such a polyethylene glycol, polypropylene glycol
  • PSTPIP polypeptides may be linked to various nonproteinaceous polymers, such as polyethylene glycol, polypropylene glycol or polyoxyalkylenes, in the manner set forth in U S Patent Nos 4,640,835, 4,496,689, 4,301, 144, 4,670,417, 4,791 ,192 or 4,179,337
  • the PSTPIP polypeptides may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, in colloidal drug delivery systems (e g posomes, albumin microspheres, microemulsions nano-particles and nanocapsules). or in macroemulsions Such techniques are disclosed in Remington's Pharmaceutical Sciences. 16th Edition, Oslo, A , Ed
  • Immunoadhesins Further derivatives of the PSTPIP polypeptides herein are the so-called "immunoadhesins" To date, more than fifty immunoadhesins have been reported in the art Immunoadhesins reported in the literature include, for example, fusions of the T cell receptor (Gascoigne et al , Proc Natl Acad Sci USA 84 2936-2940 [1987]), CD4 (Capon et al , Nature 337 525-531 [1989], Traunecker et al , Nature 339 68-70 [1989], ZettmeissI et al , DNA Cell Biol USA 9 347-353 [1990], Byrn et al , Nature 344 667-670 [1990]), L-selectin (homing receptor) (Watson et al , J Cell Biol 1 10 2221-2229 [1990], Watson et al , Nature 349 164-167
  • nucleic acid encoding the desired PSTPIP polypeptide will be fused C-terminally to nucleic acid encoding the N-terminus of an immunoglobulin constant domain sequence, however N-terminal fusions are also possible
  • the encoded chimeric polypeptide will retain at least functionally active hinge, CH2 and CH3 domains of the constant region of an immunoglobulin heavy chain Fusions are also made to the C-terminus of the Fc portion of a constant domain, or immediately N-terminal to the CHI of the heavy chain or the corresponding region of the light chain
  • the precise site at which the fusion is made is not critical, particular sites are well known and may be selected in order to optimize
  • the sequence of a native, mature PSTPIP polypeptide, or variant or fragment thereof is fused to the N-terminus of the C-termmal portion of an antibody (in particular the Fc domain), containing the effector functions of an immunoglobulin, e g IgG-1
  • an immunoglobulin e g IgG-1
  • a sequence beginning in the hinge region just upstream of the papain cleavage site (which defines IgG Fc chemically, residue 216, taking the first residue of heavy chain constant region to be 1 14 [Kabat et al , supra], or analogous sites of other immunoglobulins) is used in the fusion
  • the PSTPIP sequence full length or fragment or variant
  • the precise site at which the fusion is made is not critical
  • the PSTPIP-immunoglobulin chimeras are assembled as multimers, and particularly as homo-dimers or -tetramers (WO 91/08298) Generally, these assembled immunoglobulins will have known unit structures A basic four chain structural unit is the form in which IgG, IgD, and IgE exist A four unit is repeated in the higher molecular weight immunoglobulins, IgM generally exists as a pentamer of basic four units held together by disulfide bonds IgA globulin, and occasionally IgG globulin, may also exist in multime ⁇ c form in serum In the case of multimer, each four unit may be the same or different Various exemplary assembled PSTPIP-immunoglobulin chimeras within the scope herein are schematically diagramed below (a) AC L -AC L ,
  • V ⁇ IS an immunoglobulin light chain variable domain
  • Vp j is an immunoglobulin heavy chain variable domain
  • C ⁇ is an immunoglobulin light chain constant domain.
  • C j _ is an immunoglobulin heavy chain constant domain, n is an integer greater than 1 ,
  • Y designates the residue of a covalent cross-linking agent
  • the PSTPIP amino acid sequences can be inserted between immunoglobulin heavy chain and light chain sequences such that an immunoglobulin comprising a chimeric heavy chain is obtained
  • the PSTPIP polypeptide sequences are fused to the 3' end of an immunoglobulin heavy chain in each arm of an immunoglobulin, either between the hinge and the CH2 domain, or between the CH2 and CHS domains Similar constructs have been reported by Hoogenboom. H R et al , Mol Immunol 28 1027-1037 (1991)
  • an immunoglobulin light chain might be present either covalently associated to a PSTPIP-immunoglobulin heavy chain fusion polypeptide, or directly fused to the PSTPIP polypeptide In the former case.
  • the immunoglobulin sequences used in the construction of the immunoadhesins of the present invention are from an IgG immunoglobulin heavy chain constant domain
  • IgG-1 and IgG-3 immunoglobulin sequences are preferred.
  • ICAM- IgM (Martin et al , J Virol 67 3561-68 [1993]), and CD2-IgM (Arulanandam et al , J Exp Med 111 1439-50 [1993])
  • PSTPIP-Ig immunoadhesins which are designed for in vivo application, the pharmacokinetic properties and the effector functions specified by the Fc region are important as well
  • IgG- 1 , IgG-2 and IgG-4 all have in vivo half-lives of 21 days, their relative potencies at activating the complement system are different IgG-4 does not activate complement, and IgG-2 is significantly weaker at complement activation than IgG-1
  • IgG-2 does not bind to Fc receptors on mononuclear cells or neutrophils
  • IgG-3 is optimal for complement activation, its in vivo half-life is approximately one third of the other IgG isotypes
  • IgG-1 has only four serologically-defined allotypic sites, two of which (G lm and 2) are located in the Fc region, and one of these sites Glm l , is non- lmmunogemc
  • the potential lmmunogenicity of a ⁇ 3 lmmunoadhesin is greater than that of a ⁇ 1 lmmunoadhesin
  • PSTPIP-Ig immunoadhesins are most conveniently constructed by fusing the cDNA sequence encoding the PSTPIP portion in-frame to an Ig cDNA sequence
  • fusion to genomic Ig fragments can also be used (see, e g Gascoigne et al , Proc Natl Acad Sci USA 84 2936-2940 [1987], Aruffo et al , Ce// 61 1303-1313 [1990], Stamenkovic et al , Cell 66 1 133-1 144 [1991])
  • the latter type of fusion requires the presence of Ig regulatory sequences for expression cDNAs encoding IgG heavy-chain constant regions can be isolated based on published sequence from cDNA libraries derived from spleen or peripheral blood lymphocytes, by hybridization or by polymerase chain reaction (PCR) techniques H.
  • PCR polymerase chain reaction
  • Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, l e , the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts
  • the modifier "monoclonal” indicates the character of the antibody as not being a mixture of discrete antibodies
  • the anti-PSTPIP monoclonal antibodies of the present invention may be made using the hyb ⁇ doma method first described by Kohler & Milstein, Nature 256 495 (1975), or may be made by recombinant DNA methods [Cabilly et al , U S Pat No 4,816,567]
  • lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization
  • lymphocytes mav be immunized in vitro Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hyb ⁇ doma cell [Goding, Monoclonal Antibodies Principles and Practice, pp 59-103 (Academic Press, 1986)]
  • the hyb ⁇ doma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells
  • the culture medium for the hyb ⁇ domas typically will include hypoxanthine, aminopte ⁇ n, and thymidine (HAT medium), which substances prevent the growth of HGPRT- deficient cells
  • Preferred myeloma cells are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium
  • preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-1 1 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 cells available from
  • the binding specificity of monoclonal antibodies produced by hyb ⁇ doma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (R1A) or enzyme-linked immunoabsorbent assay (ELISA)
  • R1A radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson & Pollard, Anal Biochem 107 220 (1980)
  • the clones may be subcloned by limiting dilution procedures and grown by standard methods
  • Suitable culture media for this pu ⁇ ose include, for example, Dulbecco's Modified Eagle's Medium or RPMI-1640 medium
  • the hyb ⁇ doma cells may be grown in vivo as ascites tumors in an animal
  • the monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography
  • DNA encoding the monoclonal antibodies of the invention is readily isolated and sequenced using conventional procedures (e g , by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies)
  • the hyb ⁇ doma cells of the invention serve as a preferred source of such DNA
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells
  • the DNA also may be
  • non-immunoglobuhn polypeptides are substituted for the constant domains of an antibody of the invention, or they are substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for a PSTPIP polypeptide and another antigen-combining site having specificity for a different antigen
  • Chimeric or hybrid antibodies also may be prepared in vitro using known methods in synthetic protein chemistry, including those involving cross nking agents
  • lmmunotoxms may be constructed using a disulfide exchange reaction or by forming a thioether bond
  • suitable reagents for this pu ⁇ ose include lminothiolate and methyl-4-mercaptobuty ⁇ m ⁇ date
  • the antibodies of the invention typically will be labeled with a detectable moiety
  • the detectable moiety can be any one which is capable of producing, either directly or indirectly, a detectable signal
  • the detectable moiety may be a radioisotope, such as 3 H, 14 C, 32 P, 3 D S, or ! 25 I, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, biotin or an enzyme, such as alkaline phosphatase, ⁇ -galactosidase or horseradish peroxidase
  • the antibodies of the present invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays Zola, Monoclonal Antibodies A Manual of Techniques, pp 147-158 (CRC Press, Inc., 1987)
  • a labeled standard which may be a PSTPIP polypeptide or an immunologically reactive portion thereof
  • PSTPIP test sample analyte
  • the amount of PSTPIP polypeptide in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies
  • the antibodies generally are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound
  • Sandwich assays involve the use of two antibodies, each capable of binding to a different lmmunoge c portion, or epitope. of the protein to be detected
  • the test sample analyte is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte.
  • the second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobuhn antibody that is labeled with a detectable moiety (indirect sandwich assay)
  • sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme (in) Humanized antibodies
  • a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human
  • These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain
  • Humamzation can be essentially performed following the method of Winter and co-workers [Jones et al , Nature 321 522-525 (1986), Riechmann et al , Nature 332 323-327 (1988), Verhoeyen et al , Science 239 1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody
  • such "humanized” antibodies are chimeric antibodies (Cabilly, supra), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted
  • humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences
  • Three dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art
  • Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, l e the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen
  • FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target ant ⁇ gen(s), is achieved
  • the CDR residues are directly and most substantially involved in influencing antigen binding
  • transgenic animals e g mice
  • transgenic animals e g mice
  • J antibody heavy chain joining region
  • Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens
  • one of the binding specificities is for a PSTPIP polypeptide
  • the other one is for any other antigen
  • Methods for making bispecific antibodies are known in the art Traditionally, the recombinant production of bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two heavy chains have different specificities (Millstein and Cuello, Nature 305 537-539 (1983)) Because of the random assortment of immunoglobulin heavy and light chains, these hyb ⁇ domas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure The purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low Similar procedures are disclosed in PCT application publication No WO 93/08829 (published 13 May 1993), and in Traunecker et al
  • antibody variable domains with the desired binding specificities are fused to immunoglobulin constant domain sequences
  • the fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, and second and third constant regions of an immunoglobulin heavy chain (CH2 and CH3)
  • CH2 and CH3 second and third constant regions of an immunoglobulin heavy chain
  • the first heavy chain constant region (CH 1 ) containing the site necessary for light chain binding present in at least one of the fusions DNAs encoding the immunoglobulin heavy chain fusions and, if desired the immunoglobulin light chain, are inserted into separate expression vectors, and are cotransfected into a suitable host organism
  • This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields
  • Heteroconjugate antibodies are also within the scope of the present invention
  • Heteroconjugate antibodies are composed of two covalently joined antibodies Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U S Patent No 4,676,980), and for treatment of HIV infection (PCT application publication Nos WO 91/00360 and WO 92/200373, EP 03089)
  • Heteroconjugate antibodies may be made using any convenient cross-linking methods Suitable cross-linking agents are well known m the art, and are disclosed in U S Patent No 4,676,980, along with a number of cross- linking techniques I.
  • Peptide analogs of the PSTPIP polypeptides of the present invention are modeled based upon the three-dimensional structure of the native polypeptides
  • Peptides may be synthesized by well known techniques such as the solid-phase synthetic techniques initially described in Mer ⁇ field, J Am Chem Soc 15 2149-2154 ( 1963)
  • Other peptide synthesis techniques are, for examples, described in Bodanszky et al , Peptide Synthesis, John Wiley & Sons, 2nd Ed , 1976, as well as in other reference books readily available for those skilled in the art
  • a summary of peptide synthesis techniques may be found m Stuart and Young, Solid Phase Peptide Synthesis, Pierce Chemical Company, Rockford, IL (1984)
  • Peptides may also be prepared by recombinant DNA technology, using a DNA sequence encoding the desired peptide
  • the present invention also contemplates non-peptide (e g organic) compounds which display substantially the same surface as the peptide analogs of the present invention, and therefore interact with other molecules in a similar fashion J.
  • non-peptide e g organic
  • PSTPIP polypeptides of the present invention are useful for a variety of pu ⁇ oses
  • the PSTPIP polypeptide shown in Fig 1A is useful for identifying and isolating a PSTPIP homologue in another mammalian species
  • Native PSTPIP polypeptides and their functional equivalents are also useful in screening assays to identify antagonists or agonists of the native PSTPIP polypeptide
  • Such assays may take the form of any conventional cell-type or biochemical binding assay, and can be performed in a variety of different assay formats well known to those skilled in the art
  • PSTPIP polypeptides of the present invention are shown herein to be involved with the polymerization of actm monomers in eukaryotic cells As such, the PSTPIP polypeptides are useful in a variety of indications wherein the skilled artisan wishes to induce the polymerization of actin monomers
  • the PSTPIP polypeptides of the present invention and the nucleic acids encoding them are also useful as molecular markers of the tissues in which they are specifically expressed As such, the PSTPIP polypeptides and nucleic acids encoding them are useful for tissue typing of specific mammalian tissues
  • PSTPIP polypeptides of the present invention are also useful as protein molecular weight markers on protein gels
  • Nucleic acids encoding the PSTPIP polypeptides of the present invention are also useful for the preparation of PSTPIP polypeptides by recombinant techniques exemplified herein and in providing hybridization probes for searching cDNA and genomic libraries for the coding sequence of other PSTPIP polypeptides analogs in other species Antagonists of the PSTPIP polypeptides of the present invention are useful for inhibiting at least one biological activity of the polypeptides
  • PSTPIP polypeptides of the present invention can also be used in in vitro assays together with PTP HSCF, to identify inhibitors of the PTP-PSTPIP interaction
  • inhibitors may. for example be polypeptides, peptides or small (organic) molecules, which inhibit the PTP-PSTPIP interaction by binding to PSTPIP and/or to PTP HSCF
  • Similar assays can be used to find enzymatic inhibitors of dephosphorylation of the phosphatase
  • Such inhibitors may be useful as chemotherapeutic agents, which are able to stop or inhibit the cell division of tumor cells
  • Mutants (amino acid sequence variants) of native PSTPIP polypeptides can be used in vivo in ttansfected recombinant host cells to identify other components of the cell divisional machinery
  • regions of PSTPIP can be used in vivo in the yeast two-hybrid system, or in any functionally similar assay configuration, to identify other interacting proteins potentially involved with cell division
  • Antibodies specifically binding PSTPIP can be used, for example, to identify rapidly dividing cells, which, in turn, are used to image tumors comprised of such rapidly dividing cells
  • Nucleic acid ancoding native PSTPIP molecules can be used to isolate homologous genes specifically expressed in tumor cells, which might provide more specific targets for tumor therapy K.
  • yeast two-hybrid screening assay was performed essentially as described (Chien et al , Proc Natl Acad Sci USA 88 9578-9582 (1991) and Bartel et al , Methods Enzymol 254 241-263 (1995))
  • a C 22 j -S active site mutant of PTP HSCF (Cheng et al , (1996) supra) was cloned in frame with the Gal4 binding domain in the plasmid pPC97
  • a library of 6 x 10" individual clones was produced from Baf3 Iymphoid progenitor cells in the Gal4 activation domain plasmid pPC86 using standard procedures Yeast were transformed with both plasmids and were incubated on histidine minus plates for 3 days at 30° C Colonies which grew under these conditions were restreaked onto histidine minus plates and were tested for ⁇ -galactosidase activity (Bartel et al , (1995) supra) Col
  • PCR was performed using primers 48 BAMHI F (CGCGGATCCACCA TGATGGCCCAGCTGCAGTTC) (SEQ ID NO 9) and 48 SALFLAG R
  • PCR was performed using primers PC86F (GCGTTTGGAATCA CTAC) (SEQ ID NO 14) and p ⁇ p48 1706R (TTATAGTTTAGCGGCCGC TCACCGGTAGTCCTGGGCTGATG) (SEQ ID NO 15)
  • PC86F GCGTTTGGAATCA CTAC
  • p ⁇ p48 1706R TTATAGTTTAGCGGCCGC TCACCGGTAGTCCTGGGCTGATG
  • PCR was performed using primers p ⁇ p48 1673 F (GTACGCGTCGACC GCACTCTACGACTACACTGCACAG) (SEQ ID NO 16) and PC86R (Cl CTGGCGAAGAAGTCC) (SEQ ID NO 17) and the resulting product was digested with Sal I and Not I and subcloned into the Sal I and Not I sites of pGEX-4T-2
  • PCR was performed using primers PST38-RI (GATCGAATTCCCAGAACCTCAA GGAGAACTGC) (SEQ ID NO 18) and PST38-XHOI (GATCCTCGAGTTACACCCGTGTCCACTCTGCTGGAGGA) (SEQ ID NO 19)
  • PST38-RI GATCGAATTCCCAGAACCTCAA GGAGAACTGC
  • PST38-XHOI GTCCTCGAGTTACACCCGTGTCCACTCTGCTGGAGGA
  • Tyrosine Phosphorylation Baf3 cells were lysed in 1% Triton, 50mM HEPES, 10% glycerol and 5mM EDTA containing 1 ⁇ g/ml aprotinin, PMSF, leupeptin and pepstatin with ImM Sodium Vanadate and lOmM lodoacetic acid Cells were treated with 0 ImM Pervanadate for 4 hours before lysis Immunoprecipitations were performed in the vanadate-containing lysis buffer using 1 ⁇ g/ml anti-PSTPIP polyclonal antibody and 400 ⁇ g of Iysate protein at 4°C overnight Western blots were performed using 1 ⁇ g/ml affinity purified anti-PSTPIP or 1 5000 dilution of commercial 4G 10 anti-phosphotyrosine monoclonal (Upstate Biotech) Signal was detected by HRPO - ECL reagents (Pierce) The C 22 S mutant was as previously described (Cheng et al .
  • the PTP HSCF D 197 -A mutant was generated using PCR Mutagenesis primer D197A F (GTATATGTCCTGGCCAGCCCATGGGGTTCCCAGCAG) (SEQ ID NO 24), corresponding to nucleotide 591, and primer D197A R (GCAGGTCGACTCTAGATTACACCCGTGTCCACTCTG) (SEQ ID NO 25) which corresponds to the stop codon, were used in PCR to generate a fragment that could be cut with Mscl and Xbal pRK HA 38 WT, a plasmid which encoded the wild type enzyme under the control of the cytomegalovirus promoter (Cheng et al , (1996) supra), was digested with Clal and Mscl and the resulting 600bp fragment was ligated with the Mscl-Xbal PCR fragment into the Clal and Xbal sites of pRK tkneo A plasmid encoding the V-src oncogene under
  • COS-7 cells were transfected by electroporation Briefly, 1 5 x 10 6 COS-7 cells were mixed with 24 ⁇ g total DNA m PBS and electroporated at 960 ⁇ F, 0 22 volts (Bio-Rad Gene Pulsar) Following electroporation, cells were seeded in 10cm dishes and incubated for 3 days 10-cm dishes of transfected COS cells were washed twice with ice-cold PBS, and lysed in lml of M-RIPA (50mM T ⁇ s 7 4, 1% NP40, 0 25% DOC, 150mM NaCl, ImM sodium ortho-vanadate, ImM NaF plus CompleteTM Protease Inhibitors (Boeh ⁇ nger Mannheim)) Lysates were incubated for 15 minutes with lOO ⁇ l UltraLink Immobilized Protein A/G (Pierce) at 4°C, followed by centrifugation for 5 minutes Supernatants were collected and stored at -70°C or directly immunoprecipitate
  • PSTPIP-GST fusion protein was purified on GSH-sepharose and injected intramuscularly at 2 sites with 200 ⁇ g fusion protein and subcutaneously at multiple sites with a total of 300 ⁇ g PSTPIP-GST fusion protein in Complete Freunds Adjuvant Rabbits were boosted every 3 weeks with 100 ⁇ g fusion protein in Incomplete Freunds 15 ml of rabbit sera was reacted with 0 5mg PSTPIP-GST-GSH-Sepharose for 3 hours at 4°C with gentle rotation The resin was collected by centrifugation and washed with 10 column volumes of PBS Immunoglobulin was eluted from the affinity matrix with lOOmM acetic acid, 500mM NaCl, neutralized with NaOH, and then dialyzed overnight with PBS NIH 3T3 cells were seeded at 100,000 cells per chamber slide and allowed to adhere overnight The cells were transfected using Lipofectamine (2ug pRK PIP FLAG C/12 ul Lipofectamine in
  • Fig 1 A illustrates that the protein which interacts with PTP HSCF is a novel 415 residue molecule (predicted molecular weight -47,590 D) (SEQ ID NO 1) with significant sequence homology to the S pombe cell cycle protein.
  • CDC15p SEQ ID NO 26
  • This homology (-26% sequence similarity) stretches over the entire length of both molecules, with the exception of a large insertion of approximately 500 residues in the yeast molecule that is not found in the mammalian protein, and the yeast protein is the highest scoring homologue in the protein sequence database
  • both the mammalian ana yeast (Fankhauser, ( 1995) supra) proteins contain a potential coiled coil domain at their N-termini which is predicted both on the basis of sequence homology as well as an analysis of the mammalian sequence using the Prostruct program (Fig 1C) Within these coiled coil domains is a region with an extraordinary content of acidic and basic residues (positions 99-180 of the mammalian protein) Because the mammalian protein was isolated on the basis of an interaction with a tyrosine phosphatase, it is possible that the protein is tyrosine phosphorylated (see below), and examination of the mammalian and yeast sequences revealed 5 conserved tyrosine residues (positions 53.
  • EXAMPLE 2 Characterization of the Interaction Between PTP HSCF and PSTPIP
  • various GST fusions of either the phosphatase or the interacting protein were used to precipitate in vitro translation products of the cognate binding proteins
  • Fig 3 illustrates that precipitation of in vitro translated PTP HSCF by GST fusion proteins containing various SH3 domains as well as full length PSTPIP revealed a high degree of specificity in the interaction between the GST PSTPIP and the phosphatase
  • Fig 3 also illustrates that at this concentration of GST fusion protein (-1 microgram per ml or ⁇ 1 5 micromolar), the PSTPIP fusion protein appeared to be more efficient at precipitating the phosphatase than a polyclonal antibody directed against the enzyme or a monoclonal antibody directed against a hemagglutimn tag at the PTP N-terminus (data not shown
  • PTP HSCF The region of PTP HSCF which interacts with PSTPIP was identified by producing deletion mutants of the enzyme missing either the 20 amino acid C-termmal domain which is highly conserved m all of the PEST PTPs (Yang et al , (1993) supra, Matthews et al , (1992) supra, Cheng et al , (1996) supra, Huang et al , ( 1996) supra. Aoki et al , ( 1996) supra. Dosil et al , ( 1996) supra and Kim et al , ( 1996) supra) or both this domain as well as the longer proline.
  • Fig 4 A serine and threonine rich region C-termmal to the catalytic domain
  • Fig 4B-C reveal that deletion of the C-terminal 20 amino acid homology domain of PTP HSCF completely abolished the interaction between PTP HSCF and PSTPIP Because this region is conserved in all PEST PTPs.
  • V-src tyrosine kinase A potential tyrosine kinase which might phosphorylate PSTPIP in vivo is src
  • V-src tyrosine kinase is associated with the cytoskeleton, modulates cytoskeletal elements which resulted in profound mo ⁇ hological changes (Cooper et al , Cell 73 1051-1054 (1993), Kaplan et al , EMBO J 13 4745-4756 (1994) and Thomas et al , Nature 376 267-271 (1995)) and mediates the tyrosine phosphorylation of p80/85 cortactin (Wu et al , (1991) supra, Okamura et al , J Biol Chem 270(44) 26613- 26618 (1995), Vuo ⁇ et al , J Biol Chem 270(38) 22259-22262 (1995) and Dehio et al ,
  • S pombe CDC 15p is associated with the cortical actin cytoskeleton until it migrates to a region over the postmitotic nucleus and initiates formation of the actin- ⁇ ch cleavage furrow (Fankhauser, ( 1995) supra)
  • the protein remains associated with the cleavage furrow until the completion of cell division, when it migrates back to the region of the cell containing cortical actm
  • 3T3 cells were stained with an affinity purified polyclonal antibody directed against a GST fusion of the protein and were imaged using confocal microscopy
  • Fig 7 illustrates that the interacting protein is colocahzed to several actm-containing sites in the cell A large portion of the protein appears to be associated with the cortical actin cytoskeleton on the mtracellular side of the plasma membrane The protein also appears to co-localize with the actin stress fibers as well as in lamellipodial regions of the cell containing actin
  • N-coil 1 CAGTTCGGATCCATGATGCTGCAGAGGCTGCTGGACGGCAGG - Leu26 (SEQ ID NO 30) N-coil 2
  • CAGTTCGGATCCATGATGGAGAGGTACGGGAAGGAGCTGGTG - Glu51 SEQ ID NO 31
  • COS cells were transfected with various constructs, and after 48 hours, lysates were prepared and immunoprecipitated with antibodies to either the FLAG epitope contained at the C-termmus of PST PIP or an HA epitope contained at the N-terminus of PTP HSCF
  • the resultant blots were probed with anti-FLAG to detect PST PIP, anti-HA to detect PTP HSCF or anti-phosphotyrosine to detect levels of this modified amino acid in each protein
  • PST PIP was originally isolated as a binding partner of the PEST-type PTP, PTP HSCF, in a yeast two-hybrid screen Interestingly, all of the clones isolated in this procedure began within 10-15 amino acids of the N-terminus of PST PIP, consistent with the proposal that the N-terminus was critical for binding to PTP HSCF
  • deletions of 25 (delta 25), 50 (delta 50) and 75 (delta 75) amino acids of the N-terminus of the PST PIP coiled-coil domain were created These deletion mutants were produced by in vitro transcription/translation, and they were tested for binding to a GST fusion protein containing the C-terminal 149 ammo acids of PTP HSCF, including the proline-nch PST PIP binding site (GST-PTP HSCF) As figure 9 illustrates, the full length and delta 25 forms of PST PIP were capable of interacting with the GST PTP HSCF fusion protein, while the delta 50 and delta 75 forms were not
  • SH3 domain consists of a highly structured 60 amino acid long module which appears to fold properly when expressed in the absence of other protein domains, and this short motif is capable of binding to proline-nch peptides with relatively high affinity (Terasawa et al Nat Struc Biol 1 891-897
  • the WW domain is also a relatively small (-38 ammo acids), highly structured motif that is capable of forming an active protein when expressed in the absence of other modules (Macias et al Nature 382 646-
  • the mutagenesis of PST PIP was accomplished using the Dut/Ung " procedure (BioRad Laboratories, Richmond, CA)
  • the mutagenesis primers were designed to change 3 contiguous amino acids to alanine Mutations were spaced approximately 12 amino acids apart, with new restriction sites engineered in for identification of mutant clones
  • Primer annealing was carried out at 70°C for 10 minutes, 37°C for 10 minutes, room temperature for 5 minutes, and then on ice prior to T7 DNA polymerase addition
  • the primers used for PST PIP alanine-scan mutagenesis were (all 5' to 3') D38VE GTCTGAGGAGCTCCGCCGCAGCCTTGCAC (SEQ ID NO 43)
  • E50ER CCTTCCCGTACGCCGCCGCCGCCTGAGCTCTCTG (SEQ ID NO 44) R62K GGCCACCAGCCGCGGCTGCAATCTGCACGAGC (SEQ ID NO 45) R73TS CAGGGAGTCAAAGGCGGCCGCCAGGGAGTTCATC (SEQ ID NO 46) N84VG CTGGATGTGCGCTGGCCGCAGCCTCTGTTTGC (SEQ ID NO 47) R99EE CCTCCAAGCTTCGCAGCGCCGCAGCCAGGGCCAGGGC (SEQ ID NO 48) El 10RQ CCGCTGCTCTTTCGCTGCCGCTCGGAATTCCTCC (SEQ ID NO 49) 1122MD CTTCTGG ACACGGGCCGCGGCGGCCTCATACTTCT (SEQ ID NO 50) L132YK GGTCTTCTTGGCGGCCGCAAGCTTGCTCTTCT (SEQ ID NO 51) D 145QK GCATCCCTGCACGCCGCGGCATATAAGCTTTCTTGG ACTCCA (SEQ ID
  • Cysteines within the region of PTP HSCF binding domain of PST PIP were also mutated to alanine using the following primers (all 5' to 3') Cys36 TCCACATCCTTGGACATCTTCCTG (SEQ ID NO 60)
  • Cys 148 CATCATCTGCATCCCTGGCCTTCTGGTCATATCCCTTCTTG (SEQ ID NO 61 ) Cys 180 GGCTGACTCCTTGGACTGCTTGGC (SEQ ID NO 62) Cys213 GAAGGCCTCGGAGGTAGTCCGGTGCTC (SEQ ID NO 63) Cys235 ATGGAGAGCTGGTTGGAGTGCACCCACA (SEQ ID NO 64) Cys242 CATCATCCTTGACGGACTGCATGGAGAGCT (SEQ ID NO 65)
  • Plasmid concentrations were equalized with an empty vector containing the CMV promoter After 48 hours, lysates were prepare and immunoprecipitated with anti-FLAG monoclonal antibody Precipitates were run on SDS polyacrylamide gels, blotted, and probed with either anti-FLAG antibody or anti- phosphotyrosine antibody as previously described (Spencer et al (1997). supra) Bound antibodies were visualized using enhanced chemiluminescent reagents Results
  • NMR analysis of the WW domain from the yes kinase associated protein (YAP) (Sudol et al , J Biol Chem 270(24) 14733-14741 (1995)) likewise reveals an interaction between the conserved tryptophan residue and prolines in the proline helix recognized by this protein, although it is also possible that this conserved tryptophan is involved with the structure of the binding pocket (Macias, et al , (1996), supra.
  • Single codon mutations to alanine were made in the carboxy-terminus of PTP HSCF following the procedure described in Example 7, and using the following primers (all 5' to 3') HSCF R436 CCCTTTGGGTCGACCGATGGCCAAGTTGAAGCC (SEQ ID NO 67) HSCF P440 AGGATCTCGGGGCCCTTTGGCCCTTCCGATGCGC (SEQ ID NO 68) HSCF G442 CTGGAGGATCTCGAGGTGCTTTGGGCCTTCC (SEQ ID NO 69) HSCF P443 GGAGGATCTCGGGCCCCTTTGGGCCTTCCG (SEQ ID NO 70) HSCF R444 CTGCAGGAGGATCCGCGGGCCCTTTGGGCCTTCC (SEQ ID NO 71) HSCF P447 GTCCACTCTGCAGCAGGATCCCGGGGCCCTT (SEQ ID NO 72) HSCF W450 GTTACACCCGTGTCGCCTCTGCAGGAGGATCCCG (SEQ ID NO 73
  • PSTPIP is tyrosine phosphorylated in V-src transfected cells, and at least a subset of these phosphorylated residues appear to be substrates for the catalytic site of the bound PTP HSCF PSTPIP is localized to the cortical cytoskeleton, as well as in lamelhpodia and on stress fibers, and it appears to migrate to the actin- ⁇ ch cleavage furrow during cytokinesis Overexpression of the protein in 3T3 cells induces long filopodial structures, consistent with a role for PSTPIP in the reorganization of the cytoskeleton
  • proline rich C-terminal homology domain The nature of the high affinity binding between the proline rich C-terminal homology domain and the coiled coil region is reminiscent of that previously described for the SH3-prohne rich core interaction (Pawson, (1995) supra) In this latter case, proline helices induce the formation of highly structured small peptide domains that bind with relatively high affinity and specificity to the binding pocket of the SH3 domain, and various interactions, including salt bridges, mediate the specificity and direction ot peptide binding (Feng et al , (1995) supra) Analysis of the proline rich C-terminal homology domains of three PEST PTPs, all of which appear to inhibit the PSTPIP-PTP HSCF binding interaction with similar IC50 S , reveals that they share a proline rich core region that would be predicted to form a proline helix similar to that seen for SH3 binding sites (Yang et al , (1993) supra.
  • PSTPIP functions is suggested by the results of overexpression studies in murme 3T3 cells
  • the extended filopodial structures in many of these transfected cells are consistent with the possibility that the unregulated expression of the protein mediates an ectopic and organized assembly of actin filaments, thus resulting in a cellular protrusion containing PSTPIP and F actm
  • the striking level of lysines in the predicted coiled coil domain of this protein is consistent with previously described actin binding sites (Vandekerckhove.
  • This example illustrates preparation of an unglycosylated form of PSTPIP by recombinant expression in E coli
  • the DNA sequence encoding PSTPIP (SEQ ID NO 2) is initially amplified using selected PCR primers
  • the primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector
  • restriction enzyme sites A variety of expression vectors may be employed
  • An example of a suitable vector is pBR322 (derived from £ coli, see Bolivar et al , Gene.
  • the vector is digested with restriction enzyme and dephosphorylated
  • the PCR amplified sequences are then hgated into the vector
  • the vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the PSTPIP coding region, lambda transc ⁇ ptional terminator, and an argU gene
  • the ligation mixture is then used to transform a selected E coli strain using the methods described in Sambrook et al , supra Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing
  • Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics
  • the overnight culture may subsequently be used to inoculate a larger scale culture
  • the cells are then grown to a desired optical density, during which the expression promoter is turned on
  • the cells can be harvested by centrifugation
  • the cell pellet obtained by the centrifugation can be solubihzed using various agents known in the art, and the solubihzed PSTPIP protein can then be purified using a metal chelatmg column under conditions that allow tight binding of the protein EXAMPLE 10
  • This example illustrates preparation of a glycosylated form of PSTPIP by recombinant expression in mammalian cells
  • the vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector
  • the PSTPIP DNA is hgated into pRK5 with selected restriction enzymes to allow insertion of the PSTPIP DNA using ligation methods such as described in Sambrook et al , supra
  • the resulting vector is called pRK5-PSTPIP
  • the selected host cells may be 293 cells
  • Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics
  • About 10 ⁇ g pRK5-PSTPIP DNA is mixed with about 1 ⁇ g DNA encoding the VA RNA gene [Thimmappaya et al , Cell.
  • the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 ⁇ Ci/ml 35 S-cyste ⁇ ne and 200 ⁇ Ci/ml 35 S- methionine
  • the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel
  • the processed gel may be dried and exposed to film for a selected period of time to reveal the presence of PSTPIP polypeptide
  • the cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays
  • PSTPIP may be introduced into 293 cells transiently using the dextran sulfate method described by Somparyrac et al , Proc Natl Acad Sci . Y2 7575 (1981) 293 cells are grown to maximal density in a spinner flask and 700 ⁇ g pRK5-PSTPIP DNA is added The cells are first concentrated from the spinner flask by centrifugation and washed with PBS The DNA-dextran precipitate is incubated on the cell pellet for four hours The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 ⁇ g/ml bovine insulin and 0 1 ⁇ g/ml bovine transfer ⁇ n After about four days, the conditioned media is cent ⁇ fuged and filtered to remove cells and debris The sample containing expressed PSTPIP can then be concentrated and purified by any selected method, such as dialysis and/or
  • PSTPIP can be expressed in CHO cells
  • the pRK5-PSTPIP can be transfected into CHO cells using known reagents such as CaP0 4 or DEAE-dextran
  • the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as 35 S-meth ⁇ on ⁇ ne
  • the culture medium may be replaced with serum free medium
  • the cultures are incubated for about 6 days, and then the conditioned medium is harvested
  • the medium containing the expressed PSTPIP can then be concentrated and purified by any selected method
  • Epitope-tagged PSTPIP may also be expressed in host CHO cells
  • the PSTPIP may be subcloned out of the pRK5 vector
  • the subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector
  • the poly-his tagged PSTPIP insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones
  • the CHO cells can be transfected (as described above) with the SV40 driven vector Labeling may be performed, as described above, to verify expression
  • the culture medium containing the expressed poly-His tagged PSTPIP can then be concentrated and purified by any selected method, such as by N ⁇ 2+ - chelate affinity chromatography
  • EXAMPLE 11 Expression of PSTPIP in Yeast
  • yeast expression vectors are constructed for intracellular production or secretion of PSTPIP from the ADH2/GAPDH promoter DNA encoding PSTPIP, a selected signal peptide and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of PSTPIP
  • DNA encoding PSTPIP can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, the yeast alpha-factor secretory signal/leader sequence, and linker sequences (if needed) for expression of PSTPIP
  • yeast cells such as yeast strain ABI 10
  • yeast cells can then be transformed with the expression plasmids described above and cultured in selected fermentation media
  • the transformed yeast supernatants can be analyzed by precipitation with 10% t ⁇ chloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain
  • Recombmant PSTPIP can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters
  • the concentrate containing PSTPIP may further be purified using selected column chromatography resins EXAMPLE 12
  • the following method describes recombinant expression of PSTPIP in Baculovirus
  • the PSTPIP is fused upstream of an epitope tag contained with a baculovirus expression vector
  • epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG)
  • a variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen)
  • the PSTPIP or the desired portion of the PSTPIP (such as the sequence encoding the extracellular domain of a transmembrane protein) is amplified by PCR with primers complementary to the 5' and 3' regions The 5' primer may inco ⁇ orate flanking (selected) restriction enzyme sites
  • the product is then digested with those selected restriction enzymes and subcloned into the expression vector
  • Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGoldTM virus DNA (Pharmingen) into Spodoptera frugiperda (“Sf9”) cells (ATCC CRL 171 1) using lipofectm (commercially available from GIBCO-BRL) After 4 - 5 days of incubation at 28°C the released viruses are harvested and used for further amplifications Viral infection and protein expression is performed as described by O'Reilley et al , Baculovirus expression vectors A laboratory Manual, Oxford Oxford University Press (1994)
  • Expressed poly-his tagged PSTPIP can then be purified, for example, by N ⁇ 2+ -chelate affinity chromatography as follows Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al , Nature.
  • purification of the IgG tagged (or Fc tagged) PSTPIP can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography N. Concluding Remarks:
  • PSTPIPs Furrow-Associated Proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne de nouveaux polypeptides de type PSTPIP, qui se lient à la famille PEST des protéines tyrosine phosphatases et sont déphosphorylées par ladite famille. L'invention concerne spécifiquement des polypeptides murins naturels de type PSTPIP et leurs homologues chez d'autres mammifères, ainsi que leurs dérivés fonctionnels. L'invention concerne aussi des acides nucléiques codant ces protéines, des vecteurs contenant ces acides nucléiques et capables de les exprimer, et des cellules hôtes recombinées transformées par lesdits acides nucléiques. On décrit également des procédés induisant la polymérisation des monomères d'actine dans les cellules eucaryotes et des analyses permettant d'identifier les antagonistes et les agonistes des polypeptides de type PSTPIP de la présente invention.
PCT/US1998/001774 1997-02-07 1998-01-30 Proteines a phosphorylation de tyrosine et associees a un sillon de clivage (pstpip) WO1998035037A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU66493/98A AU731570B2 (en) 1997-02-07 1998-01-30 Tyrosine phosphorylated cleavage furrow-associated proteins (PSTPIPs)
US09/068,377 US6887705B1 (en) 1997-02-07 1998-01-30 Tyrosine phosphorylated cleavage furrow-associated proteins (PSTPIPs)
CA002277983A CA2277983C (fr) 1997-02-07 1998-01-30 Proteines a phosphorylation de tyrosine et associees a un sillon de clivage (pstpip)
JP53480098A JP3503951B2 (ja) 1997-02-07 1998-01-30 チロシンリン酸化切断溝関連タンパク質（ｐｓｔｐｉｐ）
EP98908458A EP0980426B1 (fr) 1997-02-07 1998-01-30 Proteines a phosphorylation de tyrosine et associees a un sillon de clivage (pstpip)
IL13095398A IL130953A0 (en) 1997-02-07 1998-01-30 Tyrosine phosphorylated cleavage furrow-associated proteins (pstpips)
AT98908458T ATE278016T1 (de) 1997-02-07 1998-01-30 Mit der zellteilungsfurche assoziierte tyrosinphosphorylierte proteine (pstpips)
DE69826649T DE69826649T2 (de) 1997-02-07 1998-01-30 Mit der zellteilungsfurche assoziierte tyrosinphosphorylierte proteine (pstpips)
IL130953A IL130953A (en) 1997-02-07 1999-07-14 TYROSINE PHOSPHORYLATED CLEAVAGE FURROW- ASSOCIATED PROTEINS (PSTPIPs)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79841997A 1997-02-07 1997-02-07
US08/798,419 1997-02-07
US93882997A 1997-09-29 1997-09-29
US08/938,829 1997-09-29

Publications (2)

Publication Number Publication Date
WO1998035037A1 true WO1998035037A1 (fr) 1998-08-13
WO1998035037A9 WO1998035037A9 (fr) 1999-01-07

Family

ID=27121985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/001774 WO1998035037A1 (fr) 1997-02-07 1998-01-30 Proteines a phosphorylation de tyrosine et associees a un sillon de clivage (pstpip)

Country Status (3)

Country Link
JP (1) JP3503951B2 (fr)
AU (1) AU731570B2 (fr)
WO (1) WO1998035037A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036534A1 (fr) * 1998-01-13 1999-07-22 Dana Farber Cancer Institute, Inc. CLONAGE ET CARACTERISATION D'UNE PROTEINE D'ADAPTATION SEMBLABLE A cdc-15 (CD2BP1)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2418284A1 (fr) * 2010-08-13 2012-02-15 ERA Biotech, S.A. Séquences de polypeptides induisant le corps protéiques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLOUTIER JF ET AL: "Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells", EMBO JOURNAL, vol. 15, no. 18, 1996, EYNSHAM, OXFORD GB, pages 4909 - 4918, XP002068213 *
DOSIL M ET AL: "CLONING AND CHARACTERIZATION OF FETAL LIVER PHOSPHATASE 1, A NUCLEAR PROTEIN TYROSINE PHOSPHATASE ISOLATED FROM HEMATOPOIETIC STEM CELLS", BLOOD, vol. 88, no. 12, 15 December 1996 (1996-12-15), pages 4510 - 4525, XP002034267 *
GARTON A J ET AL: "IDENTIFICATION OF 130CAS AS A SUBSTRATE FOR THE CYTOSOLIC PROTEIN TYROSINE PHOSPHATASE PTP-PEST", MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 11, November 1996 (1996-11-01), pages 6408 - 6418, XP002051430 *
SPENCER S ET AL: "PSTPIP: a tyrosine phosphorylated cleavage furrow-associated protein that is a substrate for a PEST tyrosine phosphatase.", J CELL BIOL, AUG 25 1997, 138 (4) P845-60, UNITED STATES, XP002068211 *
WU Y ET AL: "Tyrosine phosphorylation regulates the SH3-mediated binding of the Wiskott-Aldrich syndrome protein to PSTPIP, a cytoskeletal-associated protein.", J BIOL CHEM, MAR 6 1998, 273 (10) P5765-70, UNITED STATES, XP002068212 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036534A1 (fr) * 1998-01-13 1999-07-22 Dana Farber Cancer Institute, Inc. CLONAGE ET CARACTERISATION D'UNE PROTEINE D'ADAPTATION SEMBLABLE A cdc-15 (CD2BP1)
US6444439B1 (en) 1998-01-13 2002-09-03 Dana-Farber Cancer Institute Cloning and characterization of a cdc15-like adaptor protein (CD2BP1)
US6689868B1 (en) 1998-01-13 2004-02-10 Dana-Farber Cancer Institute, Inc. Cloning and characterization of a CDC 15-like adaptor protein (CD2BP1)

Also Published As

Publication number Publication date
JP3503951B2 (ja) 2004-03-08
AU731570B2 (en) 2001-04-05
AU6649398A (en) 1998-08-26
JP2001503994A (ja) 2001-03-27

Similar Documents

Publication Publication Date Title
EP0912733B1 (fr) Proteine tyrosine phosphatase, ptp lambda, analogue des ptp kappa/mu
EP1005549A2 (fr) Polypeptides de tumeur de la prostate et compositions antigenes
WO1997044458A9 (fr) Proteine tyrosine phosphatase, la ptp lambda analogue des ptp kappa/mu
AU2006202059B2 (en) Human Testis Specific Serine/Threonine Kinase
US6218109B1 (en) Mammalian checkpoint genes and proteins
AU731570B2 (en) Tyrosine phosphorylated cleavage furrow-associated proteins (PSTPIPs)
US6040437A (en) Tyrosine phosphorylated cleavage furrow-associated proteins (PSTPIPS)
US6511825B1 (en) Cell signaling polypeptides and nucleic acids
WO1998035037A9 (fr) Proteines a phosphorylation de tyrosine et associees a un sillon de clivage (pstpip)
EP0980426B1 (fr) Proteines a phosphorylation de tyrosine et associees a un sillon de clivage (pstpip)
CA2246430C (fr) Proteine tyrosine phosphatases de cellules hematopoietiques
US6887705B1 (en) Tyrosine phosphorylated cleavage furrow-associated proteins (PSTPIPs)
WO1997035019A9 (fr) Proteine tyrosine phosphatases de cellules hematopoietiques
US6111073A (en) Tyrosine phosphorylated cleavage furrow-associated proteins (PSTPIPs)
EP1443117B1 (fr) Serine/thréonine kinase spécifique des testicules de l'homme
JP2003523748A (ja) 新規ホスホジエステラーゼ７ｂ型
WO2003004532A2 (fr) Variants d'epissures de q9ul33/q9nzz4 et q9h5p3
US20040143856A1 (en) Placenta derived apoptotic factor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 130953

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 09068377

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/22-22/22, DRAWINGS, REPLACED BY NEW PAGES 1/23-23/23; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 66493/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2277983

Country of ref document: CA

Ref country code: CA

Ref document number: 2277983

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/007114

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 534800

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998908458

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998908458

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 66493/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998908458

Country of ref document: EP